Shuttle Pharmaceuticals Holdings, Inc.

Shuttle Pharmaceuticals Holdings, Inc. is a U.S.-based discovery and development stage pharmaceutical company focused on novel cancer therapies. The company’s work centers on product candidates designed to improve the effectiveness and delivery of radiation therapy and related oncology treatments.

0.06

0.06

— Shuttle Pharmaceuticals Holdings, Inc.
%
Oncology drug candidates100% Investigational pharmaceutical products designed to treat cancer and improve standard therapies.
Radiation therapy enhancement0% Compounds intended to improve the safety, reliability, or effectiveness of radiation treatment.
Clinical development services0% Internal development activities supporting preclinical work, trials, and regulatory advancement.

Shuttle Pharmaceuticals does not sell commercial products broadly; its primary stakeholders are oncology patients...

  • Future oncology treatment providersprimary

    Hospitals, cancer centers, and radiation oncology practices that would use approved therapies in patient care.

  • Clinical trial ecosystemprimary

    CROs, trial sites, investigators, and research partners supporting development of Ropidoxuridine and other candidates.

  • Regulatory and scientific stakeholderssecondary

    FDA and other oversight bodies, plus academic and clinical collaborators that influence approval and evidence generation.

The company is headquartered in the United States and conducts its development activities from a U.S. base...

  • •Headquartered in the United States
  • •Clinical development and corporate functions are U.S.-based
  • •Dependent on U.S. regulatory pathways for lead candidates
  • •No country-level revenue disclosure in the provided reports
  • •Exposure is concentrated in the U.S. biotech funding and trial ecosystem

The company’s strategy is to advance a cancer-focused pipeline from discovery into clinical testing, with emphasis on...

01
Advance Ropidoxuridine clinical trialsshort-term

Clinical data is the main value driver for a development-stage oncology company.

02
Maintain financing capacityshort-term

Development programs require ongoing external capital before product revenue exists.

03
Position the platform around radiation oncologymedium-term

A focused therapeutic niche can differentiate the pipeline and support partnering.

Shuttle Pharmaceuticals faces the typical risks of a pre-revenue biotech company: clinical failure, regulatory delays,...

critical

Clinical development failure

Pipeline value depends on trial results for Ropidoxuridine and related candidates.

Scope
Lead oncology program
Materiality
high
high

Funding and dilution risk

The company has no operating revenue and relies on equity or similar financing.

Scope
Corporate liquidity and development budget
Materiality
high
high

Regulatory approval risk

Drug candidates must satisfy safety and efficacy requirements before commercialization.

Scope
FDA and clinical pathway
Materiality
high
medium

Third-party execution risk

Trials depend on CROs, clinical sites, and vendors outside direct control.

Scope
Theradex and other service providers
Materiality
medium
Research and development expense
Higher trial activity increases reported R&D expense
Fair value of convertible notes
Can materially affect net loss and comparability
Derivative financial instruments
Can cause volatility in other expense
Stock-based compensation
Raises reported expenses without immediate cash outflow

ARROWHEAD PHARMACEUTICALS, INC.

ARWR · Pharmaceutical Preparations

RHYTHM PHARMACEUTICALS, INC.

RYTM · Pharmaceutical Preparations

INSULET CORP

PODD · Surgical & Medical Instruments & Apparatus

IMMUNIC, INC.

IMUX · Pharmaceutical Preparations

Scilex Holding Co

SCLX · Biological Products, (No Diagnostic Substances)

Phathom Pharmaceuticals, Inc.

PHAT · Pharmaceutical Preparations

: 29.4.2026